Tuesday, April 12, 2011

Upcomping Cancer Workshops 2011

Accelerating Anticancer Agent Development and Validation Workshop:

ASCO is co-sponsoring the “Accelerating Anticancer Agent Development and Validation Workshop.” A postgraduate workshop for clinical and translational investigations focused on strategic planning to develop and validate new anticancer and cancer prevention agents and pathways. This is an intensive and interactive workshop in how to design effective strategies - from clinical trial initiative, to enabling trials, to pivotal efficacy trials - leading to the development of new anticancer and prevention agents. The course is taught by a distinguished faculty from across the academic, industry, consumer, and government (FDA) sectors.

May 18 - 20, 2011
Bethesda North Marriott Hotel
Bethesda, Maryland
For more information on 2011 workshop, please go to http://www.acceleratingworkshop.org/.

2011 ASCO/AACR Workshop: Methods in Clinical Cancer Research
An Intensive Workshop in the Essentials of Effective Clinical Trial Designs of Therapeutic Interventions in the Treatment of Cancer for Clinical Fellow and Junior Faculty Clinical Researchers in All Oncology Subspecialties, including Radiation and Surgical Oncology and Radiology.
July 30 - August 5, 2011
Vail Marriott Mountain Resort
Vail, Colorado

For apply to this workshop visit http://myaacr.aacr.org/Core/Workshops/default.aspx

Wednesday, April 6, 2011

AngioDynamics 3Q profit up as oncology sales rise

ALBANY, N.Y. (AP) -- Medical device maker AngioDynamics Inc. on Tuesday reported a higher profit for its fiscal third quarter in which it posted a 19 percent rise in sales in its oncology/surgery division.

AngioDynamics said its net income rose 14 percent to $3.8 million, or 15 cents per share, in the quarter ended Feb. 28, up from $3.3 million, or, 13 cents per share, a year ago. Revenue rose to $54.6 million from $52.2 million. The revenue boost was offset by higher expenses, but lower income taxes pushed the company to a higher profit.

Analysts polled by FactSet expected net income of 13 cents per share and $54.3 million in revenue.